Fidia S.p.A. (BIT:FDA)
Italy · Delayed Price · Currency is EUR | Market Cap | 99.90K -94.1% |
| Revenue (ttm) | 21.13M -28.9% |
| Net Income | -2.19M |
| EPS | -1.15 |
| Shares Out | 16.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,429,797 |
| Average Volume | 6,923,953 |
| Open | 0.0062 |
| Previous Close | 0.0062 |
| Day's Range | 0.0056 - 0.0062 |
| 52-Week Range | 0.0056 - 0.7400 |
| Beta | 0.49 |
| RSI | 13.86 |
| Earnings Date | May 5, 2026 |
About Fidia
Fidia S.p.A., together with its subsidiaries, designs, manufactures, and sells high speed milling systems, numerical controls, milling heads, and software systems. The company offers HMS, a device for measuring and compensating geometric error on continuous or indexed bi-rotary heads and roto-tilting tables; TMSC, a device to measure length and diameter of the tool, as well as to check the shape; pushbutton panels; XPower digital drives for axis and spindle movement; and I/O Line input/output modules. It also provides software solutions include... [Read more]
Financial Performance
In 2024, Fidia's revenue was 17.53 million, a decrease of -38.98% compared to the previous year's 28.74 million. Losses were -9.30 million, 611.4% more than in 2023.
Financial StatementsNews
Market Today: Alphabet, Apple Lead as AI, Energy, FDA Move
Market Today: Alphabet, Apple Lead as AI, Energy, FDA Move
AXSM Secures FDA Approval for Auvelity in Alzheimer's Agitation Treatment
AXSM Secures FDA Approval for Auvelity in Alzheimer's Agitation Treatment
AstraZeneca (AZN) Faces FDA Advisory Committee Vote on Camizestrant
AstraZeneca (AZN) Faces FDA Advisory Committee Vote on Camizestrant
Axsome Therapeutics (AXSM) Gains FDA Approval for Auvelity in Dementia Treatment
Axsome Therapeutics (AXSM) Gains FDA Approval for Auvelity in Dementia Treatment
FDA Excludes Semaglutide, Tirzepatide, and Liraglutide from 503B Bulks List (LLY)
FDA Excludes Semaglutide, Tirzepatide, and Liraglutide from 503B Bulks List (LLY)
Axsome Therapeutics Receives FDA Approval for AXS-05 in Alzheimer's Treatment
Axsome Therapeutics Receives FDA Approval for AXS-05 in Alzheimer's Treatment
Axsome Hits Record High On Alzheimer's Agitation Approval
Axsome stock skyrocketed to a record high Thursday after the FDA approved Auvelity for agitation due to Alzheimer's disease.
NovoCure Limited (NVCR) Reports Strong Q1 2026 Results and FDA Approval Insights
NovoCure Limited (NVCR) Reports Strong Q1 2026 Results and FDA Approval Insights
AstraZeneca (AZN) Faces Setback as FDA Panel Rejects Breast Cancer Drug
AstraZeneca (AZN) Faces Setback as FDA Panel Rejects Breast Cancer Drug
Eli Lilly Rises on FDA Compounding Proposal
Eli Lilly Rises on FDA Compounding Proposal
AstraZeneca (AZN) Faces Setback as FDA Advisory Panel Questions Drug's Benefit
AstraZeneca (AZN) Faces Setback as FDA Advisory Panel Questions Drug's Benefit
TELO Receives FDA Clearance for Telomir-Zn in Breast Cancer Treatment
TELO Receives FDA Clearance for Telomir-Zn in Breast Cancer Treatment
Eli Lilly, Novo Stocks Jump as FDA Moves to Limit Compounded GLP-1 Drugs
Eli Lilly, Novo Stocks Jump as FDA Moves to Limit Compounded GLP-1 Drugs
Eli Lilly (LLY) and Novo Nordisk Surge Following FDA Proposal on GLP-1 Drugs
Eli Lilly (LLY) and Novo Nordisk Surge Following FDA Proposal on GLP-1 Drugs
FDA Proposal Targets Novo Nordisk and Eli Lilly's Weight Loss Drug Ingredients
FDA Proposal Targets Novo Nordisk and Eli Lilly's Weight Loss Drug Ingredients
Cadrenal Therapeutics (CVKD) Achieves FDA Milestone for CAD-1005
Cadrenal Therapeutics (CVKD) Achieves FDA Milestone for CAD-1005
FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies
If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines unless they appear on the FDA's drug shortage list.
FDA Reports Baby Formula Safety, Highlights Abbott (ABT) Among Compliant Products
FDA Reports Baby Formula Safety, Highlights Abbott (ABT) Among Compliant Products
Weekly Buzz: FDA Okays Saphnelo Pen, EC Clears Acromegaly Drug, SNGX Slumps, LGND Snaps Up XOMA
(RTTNews) - This week's biotech landscape witnessed regulatory approvals in the US and Europe, acquisitions, and a few trial halts, alongside positive data readouts spanning multiple therapeutic areas...
Trump administration move to reclassify cannabis sparks confusion
Order last week is only partial rescheduling, making ‘an already complex process more confusing,’ expert says The Trump administration is making good on its promise to reschedule cannabis , but only p...
FDA to Review IDYA's New Drug Application for Melanoma Treatment
FDA to Review IDYA's New Drug Application for Melanoma Treatment
‘No more fake paneer on your plate’: Maharashtra mandates full disclosure from May 1
Mumbai diners will soon know if their paneer is dairy-based or a vegetable oil substitute. Maharashtra's FDA mandates eateries to clearly label "analogue paneer" or "cheese analogue" from May 1. This ...
Biocon receives five observations from U.S. FDA after pre-license inspection
The U.S. Food and Drug Administration (FDA) has concluded a Pre-License Inspection (PLI) at Biocon's biosimilars site located at Biocon Park in Bengaluru, India. The inspection, which took place from…
4 deaths trigger watermelon scare in Mumbai; probe slows, traders pull fruit off shelves
Maharashtra FDA faces delays in testing watermelon samples linked to four deaths, as watermelons have vanished from local markets. Investigators require samples from a 5-10 km radius of the incident, ...
Pak-made illegal cosmeticsrecovered from Itwari shop
Nagpur: Maharashtra Food and Drug Administration (FDA), Nagpur Division, raided a cosmetics firm in Itwari market and seized Pakistan-origin beauty pr.